Michael Pope1, Paul R Kalra2. 1. Department of Cardiology, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Level 2, Headley Way, Headington, Oxford, OX3 9DU, UK. mtbpope@doctors.org.uk. 2. Portsmouth Hospitals NHS Trust, Portsmouth, UK.
Abstract
PURPOSE OF REVIEW: This review will highlight the frequency and prognostic importance of iron deficiency in patients with chronic heart failure. An overview of the evidence surrounding the use of both oral and intravenous iron will be presented together with discussion around what further data are required to establish what is the optimal long-term treatment strategy. RECENT FINDINGS: Several recent randomised controlled studies have suggested that intravenous iron therapy in iron deficient patients with chronic heart failure and reduced ejection fraction can improve symptoms and quality of life, at least in the short term. There is no evidence of benefit from oral iron. Iron deficiency is common in patients with chronic heart failure and is associated with a worse prognosis. Whilst oral iron therapy has been shown to be of no benefit, randomised controlled trials suggest significant improvement in symptoms and quality of life with intravenous iron treatment over 6-12 months. Data are lacking on long-term efficacy, safety and impact on hard outcomes such as death and hospitalisation. Four large trials are currently recruiting patients and will provide definitive answers to these outstanding questions.
PURPOSE OF REVIEW: This review will highlight the frequency and prognostic importance of iron deficiency in patients with chronic heart failure. An overview of the evidence surrounding the use of both oral and intravenous iron will be presented together with discussion around what further data are required to establish what is the optimal long-term treatment strategy. RECENT FINDINGS: Several recent randomised controlled studies have suggested that intravenous iron therapy in iron deficientpatients with chronic heart failure and reduced ejection fraction can improve symptoms and quality of life, at least in the short term. There is no evidence of benefit from oral iron. Iron deficiency is common in patients with chronic heart failure and is associated with a worse prognosis. Whilst oral iron therapy has been shown to be of no benefit, randomised controlled trials suggest significant improvement in symptoms and quality of life with intravenous iron treatment over 6-12 months. Data are lacking on long-term efficacy, safety and impact on hard outcomes such as death and hospitalisation. Four large trials are currently recruiting patients and will provide definitive answers to these outstanding questions.
Entities:
Keywords:
Heart failure; Intravenous iron; Iron; Iron deficiency
Authors: Aidan P Bolger; Frederick R Bartlett; Helen S Penston; Justin O'Leary; Noel Pollock; Raffi Kaprielian; Callum M Chapman Journal: J Am Coll Cardiol Date: 2006-08-28 Impact factor: 24.094
Authors: Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak Journal: Circulation Date: 2006-06-05 Impact factor: 29.690
Authors: Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos S Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake Journal: J Am Coll Cardiol Date: 2017-04-28 Impact factor: 24.094
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur J Heart Fail Date: 2016-05-20 Impact factor: 15.534
Authors: Rakesh Sharma; Darrel P Francis; Bertram Pitt; Philip A Poole-Wilson; Andrew J S Coats; Stefan D Anker Journal: Eur Heart J Date: 2004-06 Impact factor: 29.983
Authors: Karl Swedberg; James B Young; Inder S Anand; Sunfa Cheng; Akshay S Desai; Rafael Diaz; Aldo P Maggioni; John J V McMurray; Christopher O'Connor; Marc A Pfeffer; Scott D Solomon; Yan Sun; Michal Tendera; Dirk J van Veldhuisen Journal: N Engl J Med Date: 2013-03-10 Impact factor: 91.245
Authors: Darlington O Okonko; Agnieszka Grzeslo; Tomasz Witkowski; Amit K J Mandal; Robert M Slater; Michael Roughton; Gabor Foldes; Thomas Thum; Jacek Majda; Waldemar Banasiak; Constantinos G Missouris; Philip A Poole-Wilson; Stefan D Anker; Piotr Ponikowski Journal: J Am Coll Cardiol Date: 2008-01-15 Impact factor: 24.094
Authors: Eileen O'Meara; Tim Clayton; Margaret B McEntegart; John J V McMurray; Chim C Lang; Simon D Roger; James B Young; Scott D Solomon; Christopher B Granger; Jan Ostergren; Bertil Olofsson; Eric L Michelson; Stuart Pocock; Salim Yusuf; Karl Swedberg; Marc A Pfeffer Journal: Circulation Date: 2006-02-13 Impact factor: 29.690